<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873275</url>
  </required_header>
  <id_info>
    <org_study_id>08005</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-08005</secondary_id>
    <secondary_id>CDR0000637521</secondary_id>
    <secondary_id>NCI-2010-00926</secondary_id>
    <nct_id>NCT00873275</nct_id>
  </id_info>
  <brief_title>Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer</brief_title>
  <official_title>Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and&#xD;
      fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can&#xD;
      block tumor growth in different ways. Some block the ability of tumor cells to grow and&#xD;
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.&#xD;
      Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the&#xD;
      tumor. Giving ursodiol together with leucovorin calcium, fluorouracil, oxaliplatin, and&#xD;
      bevacizumab may be an effective treatment for colorectal cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of ursodiol when given&#xD;
      together with combination chemotherapy and bevacizumab in treating patients with stage IV&#xD;
      colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the active dose and/or maximum tolerated dose of ursodiol when given in&#xD;
           combination with fluorouracil, leucovorin calcium, oxaliplatin (FOLFOX regimen), and&#xD;
           bevacizumab in patients with metastatic colorectal cancer.&#xD;
&#xD;
        -  To determine the pharmacokinetics of ursodiol when given with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the systemic metabolic effects of ursodiol activation of nuclear receptor&#xD;
           farnesoid X receptor (FXR) in glucose and lipid metabolism.&#xD;
&#xD;
        -  To develop assays to detect ursodiol activation of FXR.&#xD;
&#xD;
        -  To identify and evaluate potential serum biomarkers of FXR activation.&#xD;
&#xD;
        -  To determine genes regulated by activation of FXR at target tissues.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of ursodiol.&#xD;
&#xD;
      Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1),&#xD;
      leucovorin calcium intravenously (IV) over 2 hours on days 1 and 15, fluorouracil IV over 46&#xD;
      hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90&#xD;
      minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Blood sample is collected periodically for pharmacokinetic studies. Samples are also analyzed&#xD;
      for the role of nuclear receptor farnesoid X receptor (FXR) in glucose uptake and metabolism&#xD;
      using PET scan imaging, an oral glucose tolerance test, and HbA1c levels; the effects of FXR&#xD;
      activation on lipid metabolism; and a marker for response to FXR activation via western blot.&#xD;
      Available formalin-fixed paraffin-embedded tumor tissue blocks are analyzed for FXR&#xD;
      expressing via IHC; expression of known FXR target genes via RNA analysis and real-time PCR;&#xD;
      and expression of genes involved in glucose metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2009</start_date>
  <completion_date type="Anticipated">January 13, 2025</completion_date>
  <primary_completion_date type="Actual">September 25, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of ursodiol</measure>
    <time_frame>28 days from the start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities as assessed by NCI CTCAE 3.0</measure>
    <time_frame>28 days after the last cycle of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to failure</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ursodiol</measure>
    <time_frame>8 days after start of treatment during course 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>5mg/kg IV day 1 and 15 of each 28 day course of treatment</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>Leucovorin, 5-FU and Oxaliplatin</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodiol</intervention_name>
    <description>Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
    <description>Analysis on discard tissues</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Analysis on discard tissues</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Performed on tumor blocks from the primary and the metastases from the patients on study</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography (PET)</intervention_name>
    <description>Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.</description>
    <arm_group_label>Treatment (ursodiol, combination chemotherapy, bevacizumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced, biopsy proven metastatic colorectal cancer&#xD;
&#xD;
          -  Karnofsky Performance Status &gt;= 80&#xD;
&#xD;
          -  Prior therapy completed at least 3 weeks before protocol treatment initiation with&#xD;
             recovery from any side-effects&#xD;
&#xD;
          -  Serum albumin and prealbumin within normal limits&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) within 3 x upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase within 3 x upper limit of normal&#xD;
&#xD;
          -  Serum bilirubin within normal limits&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500/ul&#xD;
&#xD;
          -  Serum creatinine within 1.5 x upper limit of normal&#xD;
&#xD;
          -  Ability to understand and sign an institutional review board (IRB) approved informed&#xD;
             consent&#xD;
&#xD;
          -  Ability to use appropriate contraception and no evidence of pregnancy in female&#xD;
             patients of reproductive potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant medical or psychiatric condition that would make treatment unsafe&#xD;
&#xD;
          -  Use of systemic steroids use within 7 days from start of trial&#xD;
&#xD;
          -  Nursing women&#xD;
&#xD;
          -  Patients unable to comply with protocol related studies and follow up&#xD;
&#xD;
          -  Weight loss of greater than 10% in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lily L. Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

